pirfenidone has been researched along with mycophenolic acid in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Burton, JM; O'Connor, P | 1 |
| Wang, L; Zhang, FC; Zhang, X | 1 |
| Albera, C; Chen, D; Chung, L; Fischer, A; Gorina, E; Khalidi, N; Khanna, D; Raghu, G; Schiopu, E; Seibold, JR; Tagliaferri, M | 1 |
| Axmann, J; Corte, TJ; Cottin, V; Fischer, A; Gilberg, F; Kirchgaessler, KU; Kreuter, M; Lederer, DJ; Maher, TM; Molina-Molina, M; Samara, K | 1 |
| Li, G; Nong, L; Wang, M; Wang, R | 1 |
| McMahan, ZH; Volkmann, ER | 1 |
| Axmann, J; Corte, TJ; Cottin, V; Gilberg, F; Kirchgaessler, KU; Kreuter, M; Maher, TM; Molina-Molina, M | 1 |
3 review(s) available for pirfenidone and mycophenolic acid
| Article | Year |
|---|---|
Novel oral agents for multiple sclerosis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Isoxazoles; Leflunomide; Minocycline; Multiple Sclerosis; Mycophenolic Acid; Propylene Glycols; Pyridones; Quinolones; Sphingosine | 2007 |
Therapeutic advances for primary biliary cholangitis: the old and the new.
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cyclosporine; Enzyme Inhibitors; Fibric Acids; Glucocorticoids; Humans; Immunosuppressive Agents; Indoles; Liver Cirrhosis, Biliary; Mesenchymal Stem Cell Transplantation; Methotrexate; Mycophenolic Acid; Pyridones; Rituximab; Tacrolimus; Ursodeoxycholic Acid; Ustekinumab | 2016 |
An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
Topics: Autoantibodies; Clinical Trials as Topic; Cyclophosphamide; Drugs, Investigational; Humans; Lung Diseases, Interstitial; Mycophenolic Acid; Pyridones; Rituximab; Scleroderma, Diffuse; Scleroderma, Systemic; Treatment Outcome | 2020 |
3 trial(s) available for pirfenidone and mycophenolic acid
| Article | Year |
|---|---|
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Mycophenolic Acid; Pyridones; Scleroderma, Systemic; Treatment Outcome | 2016 |
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Mycophenolic Acid; Progression-Free Survival; Pulmonary Fibrosis; Pyridones; Respiratory Function Tests; Treatment Outcome; Vital Capacity | 2020 |
Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use.
Topics: Double-Blind Method; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Mycophenolic Acid; Pyridones; Treatment Outcome | 2022 |
2 other study(ies) available for pirfenidone and mycophenolic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multiple eruptive dermatofibromas aggravated by mycophenolate mofetil and pirfenidone in a patient with systemic sclerosis.
Topics: Antirheumatic Agents; Female; Histiocytoma, Benign Fibrous; Humans; Lung Diseases, Interstitial; Middle Aged; Mycophenolic Acid; Pyridones; Scleroderma, Systemic; Skin; Skin Neoplasms | 2020 |